.jpg)
1 hour ago
2
Article content
VANCOUVER, British Columbia, March 27, 2026 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a pharmaceutical manufacturer specializing in products containing psychoactive and psychotropic compounds, including cannabis, is pleased to announce that wholesale cannabis products previously exported to Germany during the prior quarter have now been successfully released for sale in the German market.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
The release follows completion of required import, quality control, and market release procedures for Germany’s regulated medical cannabis market. Following this milestone, the Company has accepted a reorder for additional wholesale product.
Article content
Article content
Article content
This milestone builds on HYTN’s previously announced strategic supply framework for Germany and further demonstrates the Company’s ability to execute within highly regulated international medical cannabis markets.
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“The successful release of product into the German market is a significant commercial milestone,” said Elliot McKerr, Chief Executive Officer of HYTN. “It validates that our GMP platform meets the stringent requirements of one of the world’s most tightly regulated medical cannabis markets. The acceptance of a reorder is a positive indicator as we continue toward building recurring international revenue channels.”
Article content
HYTN believes the successful German market release of this shipment further validates the commercial progress reflected in its recent financial results and supports the Company’s strategy of expanding pharmaceutical-grade cannabis sales into highly regulated international markets
Article content
About HYTN Innovations Inc.
Article content
HYTN Innovations Inc. is a pharmaceutical company specializing in the formulation, manufacturing, marketing, and sale of products containing psychoactive and psychotropic compounds, including cannabis-derived cannabinoids. The Company focuses on serving federally regulated markets by applying pharmaceutical-grade development, manufacturing, and quality systems. HYTN advances products to market by identifying regulated market opportunities and leveraging its integrated development and commercialization platform.
Article content
Article content
For more information contact:
Elliot McKerr
Chief Executive Officer
HYTN Innovations Inc.
Article content
HYTN Investor Relations:
1.866.590.9289
[email protected]
Article content
The Canadian Securities Exchange (CSE) has not reviewed, approved, or disapproved the contents of this press release.
Article content
Forward-Looking Statements
Article content
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable securities laws. Forward-looking information relates to future events or future performance and is generally identifiable by the use of words such as “expect,” “intend,” “may,” “will,” “anticipate,” “believe,” and similar expressions, or by statements regarding matters that are not historical facts. Such statements are based on the Company’s current beliefs, assumptions, and expectations regarding future events and operating conditions.
Article content
This press release contains forward-looking information relating to, among other things: the successful release and sale of cannabis products in the German market; the acceptance and fulfillment of the reorder; the continuation and growth of commercial activity in Germany; and the Company’s ability to execute within highly regulated international medical cannabis markets.
English (US)